Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $29.75 | Total: $148.75 |
| 1 | 10 | $25.20 | Total: $252.00 |
| 1 | 25 | $21.35 | Total: $533.75 |
| 1 | 50 | $18.20 | Total: $910.00 |
| 1 | 100 | $15.75 | Total: $1,575.00 |
Overview
Ensifentrine (Ensifentrinum) is a PDE34 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
Chemical Properties
| Molecular Formula | C26H31N5O4 |
| Molecular Weight | 477.56 |
| CAS Numbers | 1884461-72-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1cc2CCn3c(cc(=Nc4c(C)cc(C)cc4C)n(CCNC(N)=O)c3=O)-c2cc1OC |
Storage and Handling
0C Short Term, -20C Long Term
References
Henrik Watz, et al. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. Int J Chron Obstruct Pulmon Dis. 2020 Sep 16;15 2199-2206.